financetom
Business
financetom
/
Business
/
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx
Jan 30, 2025 1:38 AM

04:18 AM EST, 01/30/2025 (MT Newswires) -- MaxCyte ( MXCT ) said Thursday it has acquired SeQure Dx for $4.5 million in upfront cash and up to $2.5 million in contingency payments.

SeQure Dx provides on-target and off-target editing assessment services for cell and gene therapies.

MaxCyte ( MXCT ) expects the deal to be accretive to its revenue growth.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going With UBS Shares On Wednesday?
What's Going With UBS Shares On Wednesday?
Sep 11, 2024
UBS Group AG ( UBS ) shares are trading lower on Wednesday. Sabine Keller-Busse, UBS’s Switzerland country head, affirmed the bank’s steadfast commitment to its domestic market, addressing public concerns about its plans, reported Reuters. Keller-Busse told a conference in northern Switzerland, “Underpinning this commitment, we aim to maintain our loan book in Switzerland at around 350 billion Swiss francs...
What's Going On With Mullen Automotive Stock Today?
What's Going On With Mullen Automotive Stock Today?
Sep 11, 2024
Mullen Automotive, Inc. ( MULN ) shares are trading higher on Wednesday. The company announced that its unit, Bollinger Motors, has appointed Affinity Truck Center as an official dealer. Affinity operates sales locations in Bakersfield and Fresno, California, and service centers in Paso Robles and Salinas, California. Affinity Truck Center is certified under the California Hybrid and Zero-Emission Truck and...
BriaCell Therapeutics Prices $8.5 Million Offering
BriaCell Therapeutics Prices $8.5 Million Offering
Sep 11, 2024
12:44 PM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday it has priced a best-efforts offering of about 12.3 million shares at $0.69 per share for gross proceeds of about $8.5 million. The clinical-stage biotechnology company said it expects to close the offering Thursday, with ThinkEquity as placement agent. Investors have the option to buy pre-funded...
Preview: Kairos Pharma, Ltd Set To IPO Tomorrow
Preview: Kairos Pharma, Ltd Set To IPO Tomorrow
Sep 11, 2024
Kairos Pharma, Ltd (NASDAQ:KAPA) IPO will take place September, 12 on the NASDAQ exchange under the ticker KAPA. The company is offering shares at an expected price of $4.00 per share with an insider lock-up period of 180 days ending on March 11, 2025. See also: Benzinga IPO Calendar About Kairos Pharma, Ltd Kairos Pharma, Ltd is a clinical-stage biopharmaceutical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved